GS
ALXN

George Soros’s Alexion Pharmaceuticals ALXN Stock Holding History

George Soros’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-500,001
Closed -$91.9M – 311
2021
Q2 		$91.9M Buy
+500,001
New +$85.8M 1.55% 16
2017
Q4 		– Sell
-4,800
Closed -$673K – 298
2017
Q3 		$673K Buy
+4,800
New +$652K 0.02% 149

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

George Soros's ALXN Position: Q3 2021 in Review

George Soros sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 500,001 shares — an estimated $91.9M sold.

George Soros first reported a position in ALXN in Q3 2017 and held it in 2 quarters. The position peaked at $91.9M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • George Soros reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • George Soros sold 500,001 Alexion Pharmaceuticals shares in Q3 2021, an estimated $91.9M.
  • George Soros first reported a position in Alexion Pharmaceuticals in Q3 2017 and held it in 2 quarters.
  • George Soros's Alexion Pharmaceuticals position peaked at $91.9M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Soros Fund Management's 13F filing for Q3 2021, filed 12 Nov 2021.